YD Bio Limited (YDES) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, YDES scores 44 out of 100, a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8 / 20 (ROIC -20%; FCF yield -1.93%); Whale 13F Flow at 9 / 20 (institutional accumulation and options positioning); Insider Conviction at 3 / 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 10 / 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 14 / 20 (Altman Z 13.44; Piotroski F 4/9; Debt/Equity 0.5). The weakest pillar is insider conviction, and the cash engine is also weak given negative ROIC and negative free-cash-flow yield. The forensic balance sheet is the strongest pillar, with a high Altman Z-Score and a low Debt/Equity ratio, though the Piotroski F-Score of 4/9 is mid-range rather than strong. For a prospective investor, the practical implication is that the rating weighs current cash generation and insider signals heavily against the stock; the balance-sheet strength provides some cushion, but the cash-flow and insider pillars are the primary reasons for the underperform label.

Per the SEC financials, losses widened from FY 2023 to FY 2025 while revenue grew modestly, from $0.4M to $0.6M. The gross margin is 28.1% per the market data, but operating and net margins are both -60%, and ROIC is -20%. Per the Roarable RQD rating, the Altman Z-Score is 13.44 and the Piotroski F-Score is 4/9, with a Debt/Equity ratio of 0.5. Cash rose to $6.0M in FY 2025 from $3.1M in FY 2024, but free cash flow was $-8.0M, so the cash balance reflects financing or other inflows that the source data does not detail.

Per the recent news wire, the items are: a TradingView market report (market wire, yellow); a Stock Titan item on a no-blood-draw cancer risk questionnaire for a workplace wellness app (risk watch, red); an Investing.com India item on a $10 AI cancer risk assessment tool (risk watch, red); two price-action items noting support at $5.56 (catalyst, green); and a Stock Titan page on a different company, Aspen Neuroscience (ASPE), tagged to YDES (market wire, yellow). The price-action items are technical commentary rather than fundamental events. Per the Butterfly Supply-Chain Graph, the proprietary signal is a LIQUIDITY_TAILWIND labeled "MACRO TAILWIND SCORE (96/100)," direction BULLISH, severity 94. The associated brief cites a Net Liquidity Elasticity of 6.00x and notes True Net Liquidity contracted -0.64% over four weeks to $5,746B. This is a macro-level signal; the source data does not link it to company-specific fundamentals.

• What are the trailing EPS and P/E figures, given that EPS is N/A across all reported periods?
• What is the debt position, given that debt is N/A in every reported period while Debt/Equity is listed as 0.5?
• What drove the rise in cash from $3.1M to $6.0M in FY 2025 while free cash flow was negative?
• Which specific insider and institutional transactions underlie the insider and whale pillar scores?
• Does the AI cancer risk assessment product generate reported revenue, and at what scale?